Kunshi Biotechnology is a high-tech biomedical company focused on developing innovative therapies for solid tumors, particularly through the use of macrophage-based cell therapies. The company has established four core technology platforms that address significant challenges in macrophage research and application, such as difficulties in in vitro culture and gene transduction of macrophages. These platforms enable the efficient expansion and optimization of macrophages, facilitating their use in clinical applications and cancer treatment. Notably, Kunshi's CAR-M (Chimeric Antigen Receptor Macrophage) technology is designed to target tumor cells, enhancing the immune response against various cancers, including liver cancer and other solid tumors.

The company's pipeline includes several promising drug candidates, such as RR-M01, which targets HER2-positive solid tumors like ovarian and gastric cancers. Kunshi's approach leverages the unique properties of macrophages, which can effectively infiltrate tumor microenvironments and perform functions such as phagocytosis and antigen presentation. This innovative strategy aims to overcome the limitations faced by traditional T-cell therapies in solid tumors, offering new hope for patients with advanced cancers. The ongoing clinical trials and research initiatives underscore Kunshi Biotechnology's commitment to advancing cancer treatment through cutting-edge cellular therapies.

China

Kunshi Biotechnology is a privately held company located in Kunshan City, Jiangsu Province. The company is involved in high-level research and production in the biotechnology field.

Kunshi Biotechnology

Company Details